Life Science & Biotech

Report: Indiana boasts four nation-leading life sciences clusters

June 30, 2014
J.K. Wall
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
More

Merck's exit pushes Endocyte shares lower

June 18, 2014
 IBJ Staff
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
More

Medtronic to acquire device maker Covidien for $42.9B

June 16, 2014
Bloomberg News
Medtronic Inc., the second-largest maker of medical devices, will be based in Ireland after the acquisition for tax advantages.
More

Sale ends 83-year run for Indy’s Harlan Laboratories

June 14, 2014
Greg Andrews
Whether the merger of the former rivals is good for Indianapolis will play out in the coming months. Huntingdon has 1,200 employees, most of them in the United Kingdom and Princeton, N.J. Harlan has about 2,300 employees worldwide, including 300 locally.
More

Former Riley Hospital CEO Pescovitz to join Eli Lilly

June 11, 2014
J.K. Wall
Dr. Ora Pescovitz is returning to Indianapolis after spending the past five years as CEO of the University of Michigan Health System.
More

Lab software firm raises $8.5M, names new CEO

June 9, 2014
Dan Human
A San Diego venture capital firm has made a big bet on Indigo BioSystems Inc., which just installed its founder as the new chief executive.
More

Isotope maker plans $40M project in Noblesville

May 28, 2014
Andrea Muirragui Davis
Radiopharmaceuticals maker Zevacor Molecular plans to open a $40 million isotope-production facility in Noblesville, creating nearly 50 good-paying jobs within five years.
More

Drugmaker hid diabetes drug’s cancer risks, lawyer says

May 19, 2014
Bloomberg News
Takeda Pharmaceutical Co. executives covered up the cancer risks of its diabetes medicine Actos to protect billions of dollars in sales, a lawyer for two women argued.
More

Algaeon to take big step after landing $2.75M

May 12, 2014
Dan Human
An Indianapolis-based biotech company plans to use $2.75 million in new funding to begin commercial production of its algae-based nutritional supplements, the firm announced Monday.
More

Life sciences critical mass elusive in Indiana after years of effortRestricted Content

May 10, 2014
J.K. Wall
Attempts to build the sector are making headway, but Indiana still lags leading states.
More

U.S. House votes to revive expired research tax credit

May 9, 2014
Bloomberg News
The 274-131 vote follows calls to restore the credit by a coalition of companies including Indianapolis-based Eli Lilly and Co. and Texas Instruments Inc.
More

IU plots $200M life sciences hub in former Wishard Hospital

May 3, 2014
Dan Human
The envisioned 26-acre, $200-million-or-more complex would bridge IU’s School of Medicine with the city’s life sciences firms, including those at the nascent 16 Tech, a business park.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Zimmer shares hit 13-year high on Biomet deal

April 24, 2014
Bloomberg News
The deal will help Zimmer, a maker of artificial hips and knees, take on Johnson & Johnson, the No. 1 manufacturer in the now-growing $45 billion market.
More

Dow AgroSciences reports record quarterly results

April 23, 2014
 IBJ Staff and Bloomberg News
The Indianapolis-based subsidiary of the country's largest chemical maker achieved all-time highs in revenue and earnings in the first quarter.
More

Blockbuster deal: Eli Lilly paying $5.4B for Novartis Animal Health

April 22, 2014
 IBJ Staff
Eli Lilly and Co. has agreed to pay $5.4 billion for Novartis Animal Health in the second-largest deal in the company's history. The acquisition is part of a blockbuster three-way drug deal.
More

Lilly wins approval for potential blockbuster drug

April 21, 2014
Bloomberg News
The Indianapolis-based pharmaceutical maker gets a much-needed boost with FDA approval for gastric-cancer drug ramucirumab, which quickly could account for $1 billion in annual sales.
More

Endocyte raises another $100M in stock offering

April 7, 2014
J.K. Wall
Another public stock offering by the West Lafayette-based drugmaker swells its war chest for cancer drug development to $225 million.
More

Dow Agro parent sets stage for sale or spinoffRestricted Content

March 29, 2014
J.K. Wall
Dow AgroSciences LLC is likely to become a stand-alone public company in the next three years, according to some Wall Street analysts—if the wunderkind division of Dow Chemical Co. lives up to sky-high expectations.
More

Endocyte stock doubles after key approval in Europe

March 21, 2014
Bloomberg News, J.K. Wall
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
More

Dow Agro CEO retiring as divesture speculation returns

March 21, 2014
 Bloomberg News and IBJ Staff
Dow AgroSciences is getting a new chief, the company said Friday. Meanwhile, the CEO of parent company Dow Chemical says Dow Agro could be sold off in a year or two.
More

Biomet plans $40.5 million upgrade, 150 jobs

March 16, 2014
Associated Press
Biomet's project calls for building renovations and adding 3-D printing and optical scanning technology. The Warsaw-based company would also upgrade an incubation center for surgeons interested in introducing a new product, technology or technique.
More

Purdue-based cancer imaging firm lands $15M in funding

March 11, 2014
J.K. Wall
OnTarget Laboratories LLC's technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
More

Dow AgroSciences nears jackpot from genetic engineering

March 8, 2014
Dan Human
Dow AgroSciences LLC is spending millions of dollars and racking up hundreds of patents as its expands ever deeper in the burgeoning global market for genetically modified crops and pesticides.
More

Biomet files to sell shares in IPO to pay down debt

March 7, 2014
Bloomberg News
Indiana-based Biomet Group Inc., a closely held maker of orthopedic medical devices, had been publicly traded until 2007 when it was acquired by the group of private equity firms.
More
Page  1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT